Flotetuzumab

{
  "id": "MLC-T-ONC-013623",
  "term": "Flotetuzumab",
  "field": "Oncology and biomedicine",
  "definition": "An anti-CD123/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Flotetuzumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of flotetuzumab, this bispecific antibody simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.",
  "synonyms": [
    "CD123 x CD3 dual affinity re-targeting bi-specific antibody MGD006",
    "CD123 x CD3 DART bi-specific antibody MGD006",
    "anti-CD123/CD3 monoclonal antibody MGD006"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/flotetuzumab/"
}